P2, N=21, Completed, University of Wisconsin, Madison | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Sep 2024 | Trial primary completion date: Mar 2025 --> Apr 2024

P2, N=229, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Oct 2023 --> Feb 2025

P3, N=700, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2029 --> Oct 2029 | Trial primary completion date: Jun 2029 --> Oct 2029

P1, N=72, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2027 --> Aug 2027 | Trial primary completion date: Feb 2027 --> Aug 2027

P1, N=64, Not yet recruiting, Takeda

P4, N=250, Recruiting, Louisiana State University Health Sciences Center in New Orleans | N=150 --> 250 | Trial completion date: Mar 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Dec 2025

P2, N=16, Terminated, M.D. Anderson Cancer Center | N=60 --> 16

P1/2, N=645, Not yet recruiting, Shanghai Institute Of Biological Products

P4, N=103, Completed, University of Michigan | N=200 --> 103 | Recruiting --> Completed

To overcome these limitations, we developed an injectable thermosensitive hydrogel (LC-Gel) that incorporates the oncolytic peptide LTX-315 and the chemokine CCL21 to generate in situ DC vaccines aimed at enhancing anti-tumor immunity...Moreover, LC-Gel is shown to trigger long-term immune memory for eliciting a distant anti-tumor effect. In summary, our study introduces an innovative in situ DC vaccination strategy using an injectable oncolytic hydrogel platform for cancer immunotherapy.

P3, N=1325, Completed, Emory University | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Feb 2025

P2, N=421, Active, not recruiting, Inventprise Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026

P2, N=400, Active, not recruiting, Vaxart | N=10000 --> 400 | Recruiting --> Active, not recruiting

P1/2, N=44, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting

P1, N=190, Recruiting, Boehringer Ingelheim | Trial primary completion date: May 2027 --> Dec 2027

The present study using a coronavirus disease 2019 mouse model demonstrated that ARNAX potently induces cellular immunity in addition to humoral immunity with minimal induction of inflammatory cytokines. Therefore, ARNAX has the potential to be used as a potent and welltolerated adjuvant for vaccines against pandemic viruses emerging in the future.

P2, N=135, Completed, Vaxart | Active, not recruiting --> Completed

P=N/A, N=1, Active, not recruiting, Pfizer | Trial completion date: May 2025 --> May 2029

P3, N=9320, Active, not recruiting, Novavax | Not yet recruiting --> Active, not recruiting

P2, N=66, Terminated, Vaxart | Completed --> Terminated; The study drug was no longer available.

P2, N=900, Active, not recruiting, Pfizer | Trial completion date: May 2030 --> Aug 2030 | Trial primary completion date: Nov 2025 --> Feb 2026

P2, N=126, Recruiting, TolerogenixX GmbH | Trial completion date: Jun 2027 --> Dec 2028 | Trial primary completion date: Jun 2025 --> Dec 2026

P=N/A, N=1, Not yet recruiting, Pfizer

P2, N=150, Completed, Technovalia, Pty Ltd | Active, not recruiting --> Completed

PDT plus rh-IFN-α2b suppository can effectively improve HPV negative conversion, accelerate vaginal microecology recovery, and modulate serum inflammatory responses in high-risk HPV patients after LEEP.

Overall, the results of this study demonstrated that LTX-315 plus anti-CTLA-4 antibody could synergistically improve the immunosuppressive microenvironment of residual tumors and induce a strong anti-tumor immunity after iRFA of HCC. This combination treatment strategy may offer a new alternative to reduce the tumor recurrence after RFA of malignant solid tumors with large sizes or in high-risk locations.

The addition of UV1 to pembrolizumab was safe but did not show an efficacy signal in this study population.

This materials system served as a physical antigen-presenting structure for which dendritic cells and other immune-stimulating cells are recruited and activated (WDVAX). In this first clinical trial of a macroscale biomaterial-based vaccine, WDVAX treatment was found to be feasible and induced immune activation in melanoma patients.

P3, N=8057, Completed, Sanofi Pasteur, a Sanofi Company | Active, not recruiting --> Completed

P2, N=48, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed | N=400 --> 48

P2, N=12, Completed, Mirror Biologics, Inc. | Phase classification: P2a --> P2

P3, N=500, Recruiting, Pfizer | Not yet recruiting --> Recruiting

P4, N=180, Sanofi Pasteur

P1, N=450, Sanofi Pasteur Inc.

P2, N=245, Recruiting, Iovance Biotherapeutics, Inc. | N=178 --> 245

P1, N=18, Completed, University of North Carolina, Chapel Hill | Active, not recruiting --> Completed

P3, N=17935, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting

P2, N=40, Not yet recruiting, PharmaJet, Inc.

P2, N=110, Recruiting, LimmaTech Biologics AG | Not yet recruiting --> Recruiting | Trial completion date: Nov 2025 --> Feb 2026 | Trial primary completion date: May 2025 --> Oct 2025

P1/2, N=177, Active, not recruiting, BioNTech SE | Trial primary completion date: Sep 2025 --> May 2025

P1, N=45, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Mar 2024 --> Feb 2025

P1, N=17, Terminated, IconOVir Bio | N=44 --> 17 | Trial completion date: Dec 2026 --> Dec 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Dec 2024; Lack of Demonstrated Clinical Activity